Clinical Endoscopy

The Korean Society of Gastrointestinal Endoscopy (대한소화기내시경학회)
권호 표지
DOI QR코드

DOI QR Code

Potassium-competitive acid blocker-associated gastric mucosal lesions

  • Kimitoshi Kubo (Department of Gastroenterology, National Hospital Organization Hakodate National Hospital) ;
  • Noriko Kimura (Department of Pathology, National Hospital Organization Hakodate National Hospital) ;
  • Mototsugu Kato (Department of Gastroenterology, National Hospital Organization Hakodate National Hospital)
  • Received : 2023.11.02
  • Accepted : 2023.11.27
  • Published : 2024.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Since the introduction of vonoprazan, a potassium-competitive acid blocker (P-CAB), it has been demonstrated to reversibly inhibit gastric acid secretion by engaging in potassium-competitive ionic binding to H+/K+-ATPase. In contrast, proton pump inhibitors (PPIs) achieve H+/K+-ATPase inhibition through covalent binding to cysteine residues of the proton pump. Reported cases have indicated an emerging trend of P-CAB-related gastropathies, similar to those associated with PPIs, as well as unique gastropathies specific to P-CAB use, such as the identification of web-like mucus. Pathologically, parietal cell profusions, which show a positively correlated with hypergastrinemia, have a higher incidence in P-CAB users compared to PPI users. Thus, this review aims to summarize the endoscopic and pathological findings reported to date concerning P-CAB-related gastric mucosal lesions. Additionally, it seeks to discuss the differences between the PPIs and P-CABs in terms of the formation and frequency of associated gastropathies. This review highlights the evident differences in the mechanism of action and potency of acid inhibition between P-CABs and PPIs, notably contributing to differences in the formation and frequency of associated gastropathies. It emphasizes the necessity to distinguish between P-CAB-related and PPI-related gastropathies in the clinical setting.

Keywords

References

  1. Strand DS, Kim D, Peura DA. 25 Years of proton pump inhibitors: a comprehensive review. Gut Liver 2017;11:27-37. https://doi.org/10.5009/gnl15502
  2. Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyrid in-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem 2012;55:4446-4456. https://doi.org/10.1021/jm300318t
  3. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs 2005;14:411-421. https://doi.org/10.1517/13543784.14.4.411
  4. Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000;14:1259-1266. https://doi.org/10.1046/j.1365-2036.2000.00840.x
  5. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects: a randomised open-label cross-over study. Aliment Pharmacol Ther 2015;42:719-730. https://doi.org/10.1111/apt.13325
  6. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of longterm treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990;99:621-628. https://doi.org/10.1016/0016-5085(90)90946-X
  7. Kojima Y, Takeuchi T, Sanomura M, et al. Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors?: a multicenter prospective cross-sectional study. Digestion 2018;97:70-75. https://doi.org/10.1159/000484217
  8. Wang TC, Koh TJ, Varro A, et al. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest 1996;98:1918-1929. https://doi.org/10.1172/JCI118993
  9. Cats A, Schenk BE, Bloemena E, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol 2000;31:684-690. https://doi.org/10.1053/hupa.2000.7637
  10. Kumar KR, Iqbal R, Coss E, et al. Helicobacter gastritis induces changes in the oxyntic mucosa indistinguishable from the effects of proton pump inhibitors. Hum Pathol 2013;44:2706-2710. https://doi.org/10.1016/j.humpath.2013.07.015
  11. Stolte M, Bethke B, Seifert E, et al. Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z Gastroenterol 1995;33:146-149.
  12. Declich P, Ambrosiani L, Bellone S, et al. Parietal cell hyperplasia with deep cystic dilations: a lesion closely mimicking fundic gland polyps. Am J Gastroenterol 2000;95:566-568. https://doi.org/10.1111/j.1572-0241.2000.t01-1-01814.x
  13. Kim GH. Proton pump inhibitor-related gastric mucosal changes. Gut Liver 2021;15:646-652. https://doi.org/10.5009/gnl20036
  14. Martin FC, Chenevix-Trench G, Yeomans ND. Systematic review with meta-analysis: fundic gland polyps and proton pump inhibitors. Aliment Pharmacol Ther 2016;44:915-925. https://doi.org/10.1111/apt.13800
  15. Iwamuro M, Shiraha H, Okada H. Gastric polyps' regression after potassium-competitive acid blocker cessation. J Gen Fam Med 2022;23:358-359. https://doi.org/10.1002/jgf2.552
  16. Nishimura N, Mizuno M, Matsueda K. Gastroduodenal intussusception due to vonoprazan-induced gastric polyps. Intern Med 2022;61:1305-1306. https://doi.org/10.2169/internalmedicine.8235-21
  17. Haruma K, Kinoshita Y, Yao T, et al. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. BMC Gastroenterol 2023;23:139.
  18. Shinozaki S, Osawa H, Hayashi Y, et al. Changes in gastric morphology during long-term use of vonoprazan compared to proton pump inhibitors. Singapore Med J 2022;63:283-287. https://doi.org/10.11622/smedj.2022076
  19. Hongo M, Fujimoto K; Gastric Polyps Study Group. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in Japan. J Gastroenterol 2010;45:618-624. https://doi.org/10.1007/s00535-010-0207-7
  20. Goto C, Okimoto K, Matsusaka K, et al. Long-term vonoprazan administration causes gastric fundic gland-type hyperplastic polyps and chronic bleeding. Clin J Gastroenterol 2023;16:159-163. https://doi.org/10.1007/s12328-022-01751-0
  21. Hatano Y, Haruma K, Kamada T, et al. Factors associated with gastric black spot, white flat elevated mucosa, and cobblestone-like mucosa: a cross-sectional study. Digestion 2018;98:185-193. https://doi.org/10.1159/000488796
  22. Uedo N, Yamaoka R, Yao K. Multiple white flat lesions in the gastric corpus are not intestinal metaplasia. Endoscopy 2017;49:615-616. https://doi.org/10.1055/s-0043-106434
  23. Shinozaki S, Osawa H, Miura Y, et al. The effect of proton pump inhibitors and vonoprazan on the development of 'gastric mucosal redness'. Biomed Rep 2022;16:51.
  24. Miyamoto S, Kudo T, Kato M, et al. Endoscopic ultrasonography features of gastric mucosal cobblestone-like changes from a proton-pump inhibitor. Clin J Gastroenterol 2017;10:220-223. https://doi.org/10.1007/s12328-017-0724-5
  25. Miyamoto S, Matsuno Y, Kato M, et al. Parietal cell protrusions and dilated oxyntic glands from use of vonoprazan. Am J Gastroenterol 2017;112:1899-1901. https://doi.org/10.1038/ajg.2017.364
  26. Hatano Y, Haruma K, Ayaki M, et al. Black spot, a novel gastric finding potentially induced by proton pump inhibitors. Intern Med 2016;55:3079-3084. https://doi.org/10.2169/internalmedicine.55.6974
  27. Kiso M, Ito M, Boda T, et al. Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor - a multicenter study. Scand J Gastroenterol 2017;52:828-832. https://doi.org/10.1080/00365521.2017.1322137
  28. Kubo K, Kimura N, Matsuda S, et al. Vonoprazan-associated gastric mucosal redness: a report of four cases. Intern Med 2020;59:507-511. https://doi.org/10.2169/internalmedicine.3715-19
  29. Kubo K, Kimura N, Watanabe R, et al. Vonoprazan-associated gastric mucosal redness in non-Helicobacter pylori-infected and Helicobacter pylori-eradicated stomach. Case Rep Gastroenterol 2021;15:751-758. https://doi.org/10.1159/000518292
  30. Kinoshita Y, Yamasaki T, Saruta M. Numerous white nodules during continuous administration of a potent gastric acid suppressor. Gastrointest Endosc 2021;93:766.
  31. Nishiyama N, Kobara H, Kagawa S, et al. Vonoprazan may cause white globe appearance in nonatrophic mucosa of stomach. Gastrointest Endosc 2021;93:767-768. https://doi.org/10.1016/j.gie.2020.09.037
  32. Yoshizaki T, Morisawa T, Fujinami M, et al. Propensity score matching analysis: incidence and risk factors for "stardust" gastric mucosa, a novel gastric finding potentially induced by vonoprazan. Aliment Pharmacol Ther 2021;53:94-102. https://doi.org/10.1111/apt.16151
  33. Nishiyama N, Kobara H, Ayaki M, et al. White spot, a novel endoscopic finding, may be associated with acid-suppressing agents and hypergastrinemia. J Clin Med 2021;10:2625.
  34. Iwamuro M, Tanaka T, Sakae H, et al. Two cases of white globe appearance in non-cancerous stomach. Ecancermedicalscience 2018;12:856.
  35. Miwa W, Hiratsuka T, Sato K, et al. Development of white globe appearance lesions in the noncancerous stomach after vonoprazan administration: a report of two cases with a literature review. Clin J Gastroenterol 2021;14:48-58. https://doi.org/10.1007/s12328-020-01243-z
  36. Miwa W, Hiratsuka T, Sato K, et al. Marked reduction in the number of white globe appearance lesions in the noncancerous stomach after exchanging vonoprazan for esomeprazole treatment: a follow-up case report. Clin J Gastroenterol 2021;14:1046-1051. https://doi.org/10.1007/s12328-021-01437-z
  37. Haruma K, Kato M, Inoue K, et al. Kyoto classification of gastritis. 3rd ed. Nihon Medical Center; 2023.